- Home
- ABL vs LAB Comparison
ABL vs LAB Comparison
Compare ABL & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- LAB
- Stock Information
- Founded
- ABL 2004
- LAB 1999
- Country
- ABL United States
- LAB United States
- Employees
- ABL N/A
- LAB N/A
- Industry
- ABL Investment Managers
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- ABL Finance
- LAB Industrials
- Exchange
- ABL Nasdaq
- LAB Nasdaq
- Market Cap
- ABL 661.9M
- LAB 473.2M
- IPO Year
- ABL N/A
- LAB 2011
- Fundamental
- Price
- ABL $7.15
- LAB $1.26
- Analyst Decision
- ABL Strong Buy
- LAB Buy
- Analyst Count
- ABL 3
- LAB 2
- Target Price
- ABL $12.83
- LAB $2.50
- AVG Volume (30 Days)
- ABL 661.4K
- LAB 1.2M
- Earning Date
- ABL 08-07-2025
- LAB 08-11-2025
- Dividend Yield
- ABL N/A
- LAB N/A
- EPS Growth
- ABL N/A
- LAB N/A
- EPS
- ABL N/A
- LAB N/A
- Revenue
- ABL $161,724,466.00
- LAB $172,271,000.00
- Revenue This Year
- ABL $77.22
- LAB N/A
- Revenue Next Year
- ABL $29.93
- LAB N/A
- P/E Ratio
- ABL N/A
- LAB N/A
- Revenue Growth
- ABL 69.56
- LAB 76.33
- 52 Week Low
- ABL $4.60
- LAB $0.92
- 52 Week High
- ABL $10.95
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- ABL 77.06
- LAB 48.12
- Support Level
- ABL $6.23
- LAB $1.15
- Resistance Level
- ABL $7.03
- LAB $1.35
- Average True Range (ATR)
- ABL 0.27
- LAB 0.08
- MACD
- ABL 0.08
- LAB -0.00
- Stochastic Oscillator
- ABL 99.29
- LAB 55.00
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.